Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Adenocarcinoma × apalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 17 Sleep Initiation and Maintenance Disorders 1 Prostatic Diseases 1 Prostate Cancer With ≤10 Bone Metastases 1 Neoplasm Metastasis 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 High-Risk and Oligometastatic Prostate Cancer 1 High Risk Prostate Cancer 1 Hematologic Neoplasms 1 Genital Diseases, Male 1 Fatigue 1 Depression 1 Adenocarcinoma 1

Interventions

pembrolizumab 8 Oxaliplatin 8 Fluorouracil 7 Leucovorin 6 Gemcitabine 5 Docetaxel 5 cemiplimab 4 Blood Specimen Collection 4 zolbetuximab 3 Taxes 3 Radiotherapy 3 Paclitaxel 3 Nivolumab 3 Cyclophosphamide 3 Capecitabine 3 trastuzumab deruxtecan 2 fludarabine 2 enzalutamide 2 durvalumab 2 darolutamide 2 alpha-2'-deoxythioguanosine 2 Trastuzumab 2 Standard of Care 2 Radiosurgery 2 Irinotecan 2 Folfox protocol 2 Dexamethasone 2 Cisplatin 2 130-nm albumin-bound paclitaxel 2 tucatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-01-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡